JP2022535195A5 - - Google Patents
Info
- Publication number
- JP2022535195A5 JP2022535195A5 JP2021568909A JP2021568909A JP2022535195A5 JP 2022535195 A5 JP2022535195 A5 JP 2022535195A5 JP 2021568909 A JP2021568909 A JP 2021568909A JP 2021568909 A JP2021568909 A JP 2021568909A JP 2022535195 A5 JP2022535195 A5 JP 2022535195A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition according
- patient
- heart failure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064503A JP2025106475A (ja) | 2019-05-19 | 2025-04-09 | 収縮不全の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849936P | 2019-05-19 | 2019-05-19 | |
| US62/849,936 | 2019-05-19 | ||
| US201962852739P | 2019-05-24 | 2019-05-24 | |
| US62/852,739 | 2019-05-24 | ||
| PCT/US2020/033438 WO2020236736A1 (en) | 2019-05-19 | 2020-05-18 | Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064503A Division JP2025106475A (ja) | 2019-05-19 | 2025-04-09 | 収縮不全の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535195A JP2022535195A (ja) | 2022-08-05 |
| JP2022535195A5 true JP2022535195A5 (cg-RX-API-DMAC7.html) | 2023-05-31 |
Family
ID=70978663
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568909A Withdrawn JP2022535195A (ja) | 2019-05-19 | 2020-05-18 | 収縮不全の処置 |
| JP2025064503A Pending JP2025106475A (ja) | 2019-05-19 | 2025-04-09 | 収縮不全の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064503A Pending JP2025106475A (ja) | 2019-05-19 | 2025-04-09 | 収縮不全の処置 |
Country Status (16)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210053939A1 (en) | 2019-07-16 | 2021-02-25 | MyoKardia, Inc. | Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
| WO2021052441A1 (zh) | 2019-09-20 | 2021-03-25 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 |
| JP7832128B2 (ja) * | 2020-06-15 | 2026-03-17 | マイオカーディア,インク | 心房機能不全の治療 |
| NL2026511B1 (en) * | 2020-09-21 | 2022-05-24 | Sulfateq Bv | Compounds for treatment of heart failure |
| WO2023102452A1 (en) * | 2021-12-02 | 2023-06-08 | Tenax Therapeutics, Inc. | Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure |
| CN116082326B (zh) * | 2022-12-16 | 2024-12-27 | 药康众拓(江苏)医药科技有限公司北京分公司 | 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2403533A (en) * | 2003-06-30 | 2005-01-05 | Orion Corp | Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof |
| WO2005117882A2 (en) * | 2004-04-20 | 2005-12-15 | Incyte Corporation | Hydroxamic acid derivatives as metalloprotease inhibitors |
| US8324178B2 (en) * | 2008-10-31 | 2012-12-04 | The Regents Of The University Of California | Method of treatment using alpha-1-adrenergic agonist compounds |
| JP2014088342A (ja) * | 2012-10-30 | 2014-05-15 | Kowa Company Ltd | ベンゾオキサジアゾール誘導体を有効成分とするmk2阻害剤 |
| SG11201705928XA (en) * | 2015-01-22 | 2017-08-30 | Myokardia Inc | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) |
| JP2020526483A (ja) * | 2017-06-30 | 2020-08-31 | アムジエン・インコーポレーテツド | 心筋節活性化剤で心不全を治療する方法 |
| WO2019006325A1 (en) * | 2017-06-30 | 2019-01-03 | Equalaire Systems, Inc. | VENT CAP OF HUB CAP |
-
2020
- 2020-05-18 SG SG11202112723PA patent/SG11202112723PA/en unknown
- 2020-05-18 KR KR1020217041155A patent/KR20220009440A/ko active Pending
- 2020-05-18 CA CA3138080A patent/CA3138080A1/en active Pending
- 2020-05-18 EP EP20730898.2A patent/EP3972597A1/en active Pending
- 2020-05-18 BR BR112021023074A patent/BR112021023074A2/pt unknown
- 2020-05-18 MX MX2021014109A patent/MX2021014109A/es unknown
- 2020-05-18 US US17/612,468 patent/US20220265629A1/en not_active Abandoned
- 2020-05-18 PE PE2021001920A patent/PE20220426A1/es unknown
- 2020-05-18 AU AU2020279710A patent/AU2020279710A1/en not_active Abandoned
- 2020-05-18 CN CN202080052078.1A patent/CN114173782A/zh active Pending
- 2020-05-18 JP JP2021568909A patent/JP2022535195A/ja not_active Withdrawn
- 2020-05-18 WO PCT/US2020/033438 patent/WO2020236736A1/en not_active Ceased
- 2020-05-19 TW TW114102703A patent/TW202541801A/zh unknown
- 2020-05-19 TW TW109116586A patent/TWI874399B/zh active
-
2021
- 2021-11-11 IL IL288051A patent/IL288051A/en unknown
- 2021-11-17 MX MX2025003918A patent/MX2025003918A/es unknown
- 2021-11-18 CO CONC2021/0015505A patent/CO2021015505A2/es unknown
- 2021-11-18 CL CL2021003045A patent/CL2021003045A1/es unknown
-
2024
- 2024-12-26 US US19/001,910 patent/US20250241903A1/en active Pending
-
2025
- 2025-04-09 JP JP2025064503A patent/JP2025106475A/ja active Pending
- 2025-11-04 AU AU2025263744A patent/AU2025263744A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025106475A5 (cg-RX-API-DMAC7.html) | ||
| JP6810152B2 (ja) | サクビトリルおよびバルサルタンの組合せの新規使用 | |
| JP2023529502A5 (cg-RX-API-DMAC7.html) | ||
| LINDE‐EDELSTAM et al. | Longevity in patients with high degree atrioventricular block paced in the atrial synchronous or the fixed rate ventricular inhibited mode | |
| TWI874399B (zh) | 心縮功能障礙之治療 | |
| US20240091203A1 (en) | Methods for treating non-obstructive hypertrophic cardiomyopathy | |
| US20230233545A1 (en) | Treatment of atrial dysfunction | |
| JP2020520948A (ja) | 心不全の治療用のホルミルペプチド受容体2/リポキシンa4受容体(fpr2/alx)アゴニストの新規な使用 | |
| JP2025525913A (ja) | 閉塞性肥大型心筋症を治療するための方法 | |
| WO2024097284A1 (en) | Mavacamten and derivatives thereof for use in treating atrial dysfunction | |
| JP2021530517A5 (cg-RX-API-DMAC7.html) | ||
| Musat et al. | Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment | |
| TH2101007135A (th) | เภสัชภัณฑ์สำหรับการรักษาการทำหน้าที่ความผิดปรกติช่วงหัวใจบีบตัวและภาวะหัวใจ ล้มเหลวที่มีสัดส่วนการบีบตัวของหัวใจที่ลดลง | |
| WO2022162021A1 (en) | Verinurad compositions and methods of use | |
| de la Cruz Seoane et al. | Triaging the clinical dilemma of a suicidal attempt with Sotalol overdose presenting with ventricular tachycardia, asystole, and Torsades de Pointes | |
| JP2021020917A (ja) | サクビトリルおよびバルサルタンの組合せの新規使用 | |
| Steffen et al. | Prognostic impact of left ventricular dilatation in heart failure with mildly reduced ejection fraction | |
| WO2012020377A1 (en) | Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation | |
| Preveden et al. | Hypertrophic cardiomyopathy: Perspectives of drug therapy | |
| HK40122885A (en) | Methods for treating obstructive hypertrophic cardiomyopathy | |
| Friedrich et al. | Treatment of Chronic Heart Failure | |
| HK40061292A (en) | Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide | |
| WO2008134602A1 (en) | Levosimendan dosage regimen |